You are leaving and open the following URL" of about "be" news
be: ar/ng/dk/GOG/Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
be, ar/ng/dk/GOG/Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial 2022 be
ar/ng/dk/GOG/Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
Copyright © 2020-2021 loohk.com. All Rights Reserved.